This product is suitable for use with the?Maxpar? Metal Labeling Kits.?For metal labeling using Maxpar? Ready antibodies,?proceed directly to the step to Partially Reduce the Antibody by adding 100 ?l of Maxpar? Ready antibody to 100 ?l of 4 mM TCEP-R in a 50 kDa filter and continue with the protocol. Always refer to the latest version of Maxpar? User Guide when conjugating Maxpar? Ready antibodies.

ELISA or ELISPOT Detection: The biotinylated MAb11 antibody is useful as the detection antibody in a sandwich ELISA or ELISPOT, when used in conjunction with the purified MAb1 antibody (Cat. No. 502802/502804) as the capture antibody.

Flow Cytometry^3,5,6,10: The fluorochrome-labeled MAb11 antibody is useful for intracellular and membrane-bound immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.

Additional reported applications (for the relevant formats) include: neutralization^1,2, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections⁴ and acetone-fixed frozen tissue sections⁸, immunocytochemistry⁷, and immunofluorescence⁹. The MAb11 antibody can neutralize the bioactivity of natural or recombinant TNF-a.

Note: For testing human TNF-a in serum or plasma, BioLegend's ELISA Max? Sets (Cat. No. 430201 to 430206) are specially developed and recommended. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of human TNF-a bioactivity (Cat. No. 502922).

The Purified MAb1 antibody is useful in neutralization² and as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MAb11 antibody (Cat. No. 502904/502914) as the detecting antibody.

Clone MAb11 cross-reacts to Cat¹¹

Maxpar? is a registered trademark of Standard BioTools Inc.

1. Rathjen D, et al. 1991. Mol. Immunol. 28:79. (Neut)
2. Ablamunits V, et al. 2010. Eur. J. Immunol. 40:2891. (Neut)
3. Enr quez J, et al. 2002. Adv. Perit. Dial. 18:177. (ICFC)
4. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
5. Chen H, et al. 2005. J. Immunol. 175:591. (ICFC)
6. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed
7. Andersson U, et al. 2000. J. Exp. Med. 192:565. (ICC)
8. Moormann AM, et al. 1999. J. Infect. Dis. 180:1987. (IHC)
9. Zhao XJ, et al. 2003. J. Immunol. 170:2923. (IF)
10. Rieger R, et al. 2009. Cancer Gene Ther. 1:53-64. (FC)
11. Maksaereekul S, et al. 2009. Vaccine. 28:3754 (FC)

1. Stras SF, et al. 2020. Developmental Cell. 51(3):357-373.e5.. PubMed
2. Gruber CN, et al. 2020. Cell. 183:982. PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Beutler B, et al. 1988. Annu. Rev. Biochem. 57:505.
3. Beutler B, et al. 1989. Annu. Rev. Immunol. 7:625.
4. Tracey K, et al. 1993. Crit. Care Med. 21:S415.